Adverse metabolic consequences of HIV protease inhibitor therapy: The search for a central mechanism

Paul W. Hruz, Haruhiko Murata, Mike Mueckler

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations

Abstract

Although the clinical introduction of human immunodeficiency virus (HIV) protease inhibitors (PIs) has resulted in a dramatic decline in HIV-related morbidity and mortality, it is now recognized that PI therapy is associated with serious adverse metabolic effects, including peripheral lipoatrophy, increased visceral fat, hyperlipidemia, and insulin resistance. Despite increasing awareness of this metabolic syndrome, the etiology of these side effects remains obscure. This review critically examines current mechanistic hypotheses in the context of the available experimental data. To date, a single unifying explanation for this syndrome has not been confirmed. As data accumulate, it is becoming clear that PIs lack precision in their cellular targets and it is likely that many of the side effects of these drugs are due to inhibition of a number of unrelated molecules.

Original languageEnglish
Pages (from-to)E549-E553
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume280
Issue number4 43-4
StatePublished - Apr 1 2001

Keywords

  • Adipogenesis
  • Glucose transport
  • Human immunodeficiency virus
  • Lipodystrophy
  • Metabolic complications

Fingerprint

Dive into the research topics of 'Adverse metabolic consequences of HIV protease inhibitor therapy: The search for a central mechanism'. Together they form a unique fingerprint.

Cite this